Xenon Pharmaceuticals (XENE) announced the appointment of Darren Cline as Chief Commercial Officer and member of the Xenon senior executive team. In this role, Cline will lead commercial strategy and operations for the Company’s portfolio of product and development candidates, with initial focus on its lead Phase 3 candidate, azetukalner, and first potential launch in epilepsy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Positive Outlook for Xenon Pharmaceuticals Driven by Promising Drug Pipeline and Strategic Trial Developments
- Xenon Shareholders Approve Key Proposals at Annual Meeting
- Xenon Pharmaceuticals to Present at Global Healthcare Conference
- Xenon Pharmaceuticals Announces Equity Inducement Grants for New Employees
- Xenon Pharmaceuticals’ Earnings Call Highlights Progress and Optimism